|
1
|
Gastaldon C, Papola D, Ostuzzi G and
Barbui C: Esketamine for treatment resistant depression: A trick of
smoke and mirrors? Epidemiol Psychiatr Sci. 29(e79)2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Vasiliu O: Investigational drugs for the
treatment of depression (Part 1): Monoaminergic, orexinergic,
GABA-ergic, and anti-inflammatory agents. Front Pharmacol.
13(884143)2022.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Vasiliu O: Investigational drugs for the
treatment of depression (Part 2): Glutamatergic, cholinergic,
sestrin modulators, and other agents. Front Pharmacol.
13(884155)2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Cristea IA and Naudat F: US Food and Drug
Administration approval of esketamine and brexanolone. Lancet
Psychiatry. 6:975–977. 2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Vasiliu O: Effects of the selective
serotonin reuptake inhibitors over coagulation in patients with
depressive disorders-a systematic review and retrospective
analysis. Rom J Mil Med CXXII. 2:7–11. 2019.
|
|
6
|
Janssen-Cilag Intl. Spravato, Summary of
Product Characteristics. 2019. Retrieved online at https://www.ema.europa.eu/en/documents/product-information/spravato-epar-product-information_en.pdf.
Accessed 19 July 2022.
|
|
7
|
Hashimoto K, Kakiuchi T, Ohba H, Nishiyama
S and Tsukada H: Reduction of dopamine
D2/3 receptor binding in the
striatum after a single administration of esketamine, but not
R-ketamine: A PET study in conscious monkeys. Eur Arch Psychiatry
Clin Neurosci. 267:173–176. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Salahudeen MS, Wright CM and Peterson GM:
Esketamine: New hope for the treatment of treatment-resistant
depression? A narrative review. Ther Adv Drug Saf.
11(2042098620937899)2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Tomasetti C, Montemitro C, Fiengo ALC,
Santone C, Orsolini L, Valchera A, Carano A, Pompili M, Serafini G,
Perna G, et al: Novel pathways in the treatment of major
depression: Focus on the glutamatergic system. Curr Pharm Des.
25:381–387. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Shin C and Kim YK: Ketamine in major
depressive disorder: Mechanisms and future perspectives. Psychiatry
Investig. 17:182–192. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Homayoun H and Moghaddam B: NMDA receptor
hypofunction produces opposite effects on prefrontal cortex
interneurons and pyramidal neurons. J Neurosci. 27:11496–11500.
2007.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zarate CA Jr, Singh JB, Quiroz JA, De
Jesus G, Denicoff KK, Luckenbaugh DA, Manji HK and Charney DS: A
double-blind, placebo-controlled study of memantine in the
treatment of major depression. Am J Psychiatry. 163:153–155.
2006.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zarate CA Jr, Mathews D, Ibrahim L, Chaves
JF, Marquardt C, Ukoh I, Jolkovsky L, Brutsche NE, Smith MA and
Luckenbaugh DA: A randomized trial of a low-trapping nonselective
N-methyl-D-aspartate channel blocker in major depression. Biol
Psychiatry. 74:257–264. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
De Berardis D, Tomasetti C, Pompili M,
Serafini G, Vellante F, Fornaro M, Valchera A, Perna G, Volpe U,
Martinotti G, et al: An update on glutamatergic system in suicidal
depression and on the role of esketamine. Curr Top Med Chem.
20:554–584. 2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Singh JB, Fedgchin M, Daly E, Xi L, Melman
C, De Bruecker G, Tadic A, Sienaert P, Wiegand F, Manji H, et al:
Intravenous esketamine in adult treatment-resistant depression: A
double-blind, double-randomization, placebo-controlled study. Biol
Psychiatry. 80:424–431. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Pompili M: Intranasal esketamine and
current suicidal ideation with intent in major depression disorder:
Beat the clock, save a life, start a strategy. Front Psychiatry.
11(325)2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Daly EJ, Singh JB, Fedgchin M, Cooper K,
Lim P, Shelton RC, Thase ME, Winokur A, Van Nueten L, Manji H and
Drevets WC: Efficacy and safety of intranasal esketamine adjunctive
to oral antidepressant therapy in treatment-resistant depression: A
randomized clinical trial. JAMA Psychiatry. 75:139–148.
2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
De Berardis D, Fornaro M, Valchera A,
Cavuto M, Perna G, Di Nicola M, Serafini G, Carano A, Pompili M,
Vellante F, et al: Eradicating suicide at its roots: Preclinical
bases and clinical evidence of the efficacy of ketamine in the
treatment of suicidal behaviors. Int J Mol Sci.
19(2888)2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Bernstein HG, Tausch A, Wagner R, Steiner
J, Seeleke P, Walter M, Dobrowolny H and Bogerts B: Disruption of
glutamate-glutamine-GABA cycle significantly impacts on suicidal
behaviour: Survey of the literature and own findings on glutamine
synthetase. CNS Neurol Disord Drug Targets. 12:900–913.
2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Tomasetti C, Iasevoli F, Buonaguro EF, De
Berardis D, Fornaro M, Fiengo AL, Martinotti G, Orsolini L,
Valchera A, Di Giannantonio M and de Bartolomeis A: Treating the
synapse in major psychiatric disorders: The role of postsynaptic
density network in dopamine-glutamate interplay and
psychopharmacologic drugs molecular actions. Int J Mol Sci.
18(135)2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Schneidman ES: Suicide as psychache. J
Nerv Ment Dis. 181:145–147. 1993.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Hashimoto K and Yang C: Is (S)-norketamine
an alternative antidepressant for esketamine? Eur Arch Psychiatry
Clin Neurosci. 269:867–868. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Fedgchin M, Trivedi M, Daly EJ, Melkote R,
Lane R, Lim P, Vitagliano D, Blier P, Fava M, Liebowitz M, et al:
Efficacy and safety of fixed-dose esketamine nasal spray combined
with a new oral antidepressant in treatment-resistant depression:
Results of a randomized, double-blind, active-controlled study
(TRANSFORM-1). Int J Neuropsychopharmacol. 22:616–630.
2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Montgomery SA and Asberg M: A new
depression scale designed to be sensitive to change. Br J
Psychiatry. 134:382–389. 1979.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Popova V, Daly EJ, Trivedi M, Cooper K,
Lane R, Lim P, Mazzucco C, Hough D, Thase ME, Shelton RC, et al:
Efficacy and safety of flexibly dosed esketamine nasal spray
combined with a newly initiated oral antidepressant in
treatment-resistant depression: A randomized double-blind
active-controlled study. Am J Psychiatry. 176:428–438.
2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Floden L, Hudgens S, Jamieson C, Popova V,
Drevets WC, Cooper K and Singh J: Evaluation of individual items of
the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg
Depression Rating Scale (MADRS) in adults with treatment-resistant
depression treated with esketamine nasal spray combined with a new
oral antidepressant. CNS Drugs. 36:649–658. 2022.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Spitzer RL, Kroenke K and Williams JB:
Validation and utility of a self-report version of PRIME-MD: The
PHQ primary care study. Primary care evaluation of mental
disorders. Patient health questionnaire. JAMA. 282:1737–1744.
1999.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Ochs-Ross R, Daly EJ, Zhang Y, Lane R, Lim
P, Morrison RL, Hough D, Manji H, Drevets WC, Sanacora G, et al:
Efficacy and safety of esketamine nasal spray plus an oral
antidepressant in elderly patients with treatment-resistant
depression-TRANSFORM 3. Am J Geriatr Psychiatry. 28:121–141.
2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Correia-Melo FS, Leal GC, Vieira F,
Jesus-Nunes AP, Mello RP, Magnavita G, Caliman-Fontes AT, Echegaray
MVF, Bandeira ID, Silva SS, et al: Efficacy and safety of
adjunctive therapy using esketamine or racemic ketamine for adult
treatment-resistant depression: A randomized, double-blind,
non-inferiority study. J Affect Disord. 264:527–534.
2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Souza-Marques B, Telles M, Leal GC,
Faria-Guimarães D, Correira-Melo FS, Jesus-Nunes AP, Vieira F,
Souza L, Lins-Silva D, Mello RP, et al: Esketamine for unipolar
major depression with psychotic features: A retrospective chart
review and comparison with nonpsychotic depression. J Clin
Psychopharmacol. 42:408–412. 2022.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Fu DJ, Ionescu DF, Li X, Lane R, Lim P,
Sanacora G, Hough D, Manji H, Drevets WC and Canuso CM: Esketamine
nasal spray for rapid reduction of major depressive disorder
symptoms in patients who have active suicidal ideation with intent:
Double-blind, randomized study (ASPIRE I). J Clin Psychiatry.
81(19m13191)2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Ionescu DF, Fu DJ, Qiu X, Lane R, Lim P,
Kasper S, Hough D, Drevets WC, Manji H and Canuso CM: Esketamine
nasal spray for rapid reduction of depressive symptoms in patients
with major depressive disorder who have active suicide ideation
with intent: Results of a phase 3, double-blind, randomized study
(ASPIRE II). Int J Neuropsychopharmacol. 24:22–31. 2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Busner J and Targum SD: The clinical
global impressions scale: Applying a research tool in clinical
practice. Psychiatry (Edgmont). 4:28–37. 2007.PubMed/NCBI
|
|
34
|
Caruso CM, Ionescu DF, Li X, Qiu X, Lane
R, Turkoz I, Nash AI, Lopena TJ and Fu DJ: Esketamine nasal spray
for the rapid reduction of depressive symptoms in major depressive
disorder with acute suicidal ideation or behavior. J Clin
Psychopharmacol. 41:516–524. 2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Lindenmayer JP, Czobor P, Alphs L, Nathan
AM, Anand R, Islam Z and Chou JC: InterSePT Study Group. The
InterSePT scale for suicidal thinking reliability and validity.
Schizophr Res. 63:161–170. 2003.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Takahashi N, Yamada A, Shiraishi A,
Shimizu H, Goto R and Tominaga Y: Esketamine as add-on therapy to
oral antidepressant in Japanese patients with treatment-resistant
depression: A phase 2b randomized clinical study. BMC Psychiatry.
21(526)2021.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Araújo-de-Freitas L, Santos-Lima C,
Mendoça-Filho E, Vieira F, França RJAF, Magnavita G, Cardoso TL,
Correia-Melo FS, Leal GC, Jesus-Nunes AP, et al: Neurocognitive
aspects of ketamine and esketamine on subjects with
treatment-resistant depression: A comparative, randomized and
double-blind study. Psychiatry Res. 303(114058)2021.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Pfenninger EG, Durieux ME and Himmelseher
S: Cognitive impairment after small-dose ketamine isomers in
comparison to equianalgesic racemic ketamine in human volunteers.
Anesthesiology. 96:357–366. 2002.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Dijkstra FM, van de Loo AJ, Abdulahad S,
Bosma ER, Hartog M, Huls H, Kuijper DC, de Vries E, Solanki B,
Singh J, et al: The effects of intranasal esketamine on on-road
driving performance in patients with major depressive disorder or
persistent depressive disorder. J Psychopharmacol. 36:614–625.
2022.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Daly EJ, Trivedi MH, Janik A, Li H, Zhang
Y, Li X, Lane R, Lim P, Duca AR, Hough D, et al: Efficacy of
esketamine nasal spray plus oral antidepressant treatment for
relapse prevention in patients with treatment-resistant depression:
A randomized clinical trial. JAMA Psychiatry. 76:893–903.
2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Wajs E, Aluisio L, Holder R, Daly EJ, Lane
R, Lim R, George JE, Morrison RL, Sanacora G, Young AH, et al:
Esketamine nasal spray plus oral antidepressant in patients with
treatment-resistant depression: Assessment of long-term safety in
phase 3, open-label study (SUSTAIN-2). J Clin Psychiatry.
81(19m12891)2020.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Citrome L, DiBernardo A and Singh J:
Appraising esketamine nasal spray for the management of
treatment-resistant depression in adults: Number needed to treat,
number needed to harm, and likelihood to be helped or harmed. J
Affect Disord. 271:228–238. 2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Pompili M: Critical appraisal of major
depression with suicidal ideation. Ann Gen Psychiatry.
18(7)2019.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Swainson J, Thomas RK, Archer S, Chrenek
C, MacKay MA, Baker G, Dursun S, Klassen LJ, Chokka P and Demas ML:
Esketamine for treatment resistant depression. Expert Rev
Neurother. 19:899–911. 2019.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Sapkota A, Khurshid H, Qureshi IA, Jahan
N, Went TR, Sultan W and Alfonso M: Efficacy and safety of
intranasal esketamine in treatment-resistant depression in adults:
A systematic review. Cureus. 13(e17352)2021.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Papakostas GI, Salloum NC, Hock RS, Jha
MK, Murrough JW, Mathew SJ, Iosifescu DV and Fava M: Efficacy of
esketamine augmentation in major depressive disorder: A
meta-analysis. J Clin Psychiatry. 81(19r12889)2020.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Jawad MY, Di Vincenzo JD, Ceban F, Jaberi
S, Lui LMW, Gillissie ES, Alnafeesi Y, Rosenblat JD and McIntyre
RS: The efficacy and safety of adjunctive intranasal esketamine
treatment in major depressive disorder: A systematic review and
meta-analysis. Expert Opin Drug Saf. 21:841–852. 2022.PubMed/NCBI View Article : Google Scholar
|
